Verhamme, Peter

Rivaroxaban with or without aspirin in stable cardiovascular disease

Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 2,438

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 2,123

Idarucizumab for Dabigatran Reversal

Pollack, C. V., Reilly, P. A., Eikelboom, J., Glund, S., Verhamme, P., Bernstein, R. A., Dubiel, R., Huisman, M. V., Hylek, E. M., Kamphuisen, P. W., et al. (2015) · New England Journal of Medicine

Atrial Fibrillation Management and OutcomesBlood Coagulation and Thrombosis Mechanisms

Cited by 1,552

American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism

Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances

Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis Mechanisms

Cited by 1,489

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 879

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · Europace

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and Management

Cited by 792

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

Weitz, J. I., Lensing, A. W. A., Prins, M. H., Bauersachs, R., Beyer-Westendorf, J., Bounameaux, H., Brighton, T. A., Cohen, A. T., Davidson, B. L., Decousus, H., et al. (2017) · New England Journal of Medicine

Venous Thromboembolism Diagnosis and ManagementBlood Coagulation and Thrombosis Mechanisms

Cited by 787

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial

Connolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 754

Association of office and ambulatory blood pressure with mortality and cardiovascular outcomes

Yang, W.-Y., Melgarejo, J. D., Thijs, L., Zhang, Z.-Y., Boggia, J., Wei, F.-F., Hansen, T. W., Asayama, K., Ohkubo, T., Jeppesen, J., et al. (2019) · JAMA

Blood Pressure and Hypertension StudiesCardiovascular Health and Disease Prevention

Cited by 491

Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease

Anand, S. S., Caron, F., Eikelboom, J. W., Bosch, J., Dyal, L., Aboyans, V., Abola, M. T., Branch, K. R. H., Keltai, K., Bhatt, D. L., et al. (2018) · Journal of the American College of Cardiology

Peripheral Artery Disease ManagementAntiplatelet Therapy and Cardiovascular Diseases

Cited by 466

Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial

Bhatt, D. L., Eikelboom, J. W., Connolly, S. J., Steg, P. G., Anand, S. S., Verma, S., Branch, K. R. H., Probstfield, J., Bosch, J., Shestakovska, O., et al. (2020) · Circulation

Antiplatelet Therapy and Cardiovascular DiseasesPeripheral Artery Disease Management

Cited by 158

Weight Loss–Associated Induction of Peroxisome Proliferator–Activated Receptor-α and Peroxisome Proliferator–Activated Receptor-γ Correlate With Reduced Atherosclerosis and Improved Cardiovascular Function in Obese Insulin-Resistant Mice

Verreth, W., De Keyzer, D., Pelat, M., Verhamme, P., Ganame, J., Bielicki, J. K., Mertens, A., Quarck, R., Benhabilès, N., Marguerie, G., et al. (2004) · Circulation

Peroxisome Proliferator-Activated ReceptorsCardiovascular Disease and Adiposity

Cited by 131

Normal-tension glaucomatous optic neuropathy is related to blood pressure variability in the Maracaibo Aging Study

Melgarejo, J. D., Maestre, G. E., Mena, L. J., Lee, J. H., Petitto, M., Chávez, C. A., Calmon, G., Silva, E., Thijs, L., Al-Aswad, L. A., et al. (2021) · Hypertension Research

Glaucoma and retinal disordersBlood Pressure and Hypertension Studies

Cited by 11

SARS-CoV-2 infection causes prolonged cardiomyocyte swelling and inhibition of HIF1α translocation in an animal model COVID-19

Daems, M., Liesenborghs, L., Boudewijns, R., Simmonds, S. J., Kraisin, S., Van Wauwe, J., Cuijpers, I., Raman, J., Geuens, N., Buyten, T. V., et al. (2022) · Frontiers in Cardiovascular Medicine

COVID-19 Clinical Research StudiesViral Infections and Immunology Research

Cited by 8